BRAF and colorectal cancer: <i>UGT1A1</i> Polymorphism for Irinotecan Dose Escalation in Patients with <i>BRAF</i>-Mutated Metastatic Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI.